These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24565737)

  • 41. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of job aids on knowledge retention among Patent and Proprietary Medicine Vendors trained to administer injectable contraceptives: longitudinal results from implementation science in Nigeria.
    Chace Dwyer S; Jain A; Ishaku SM; Okunade FT; Uzomba C; Adebayo A; Tobey E
    BMC Public Health; 2019 Oct; 19(1):1362. PubMed ID: 31651273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New aspects of injectable contraception.
    Phillips OP
    Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Task-shifting the provision of DMPA-SC in the DR Congo: Perspectives from two different groups of providers.
    Hernandez JH; Akilimali P; Glover A; Emel R; Mwembo A; Bertrand J
    Contraception; 2018 Nov; 98(5):449-453. PubMed ID: 30031000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contraceptive efficacy and safety of DMPA-SC.
    Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM
    Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Community Health Workers as Social Marketers of Injectable Contraceptives: A Case Study from Ethiopia.
    Weidert K; Gessessew A; Bell S; Godefay H; Prata N
    Glob Health Sci Pract; 2017 Mar; 5(1):44-56. PubMed ID: 28275087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introduction strategies raise key questions.
    Finger WR; Keller S
    Netw Res Triangle Park N C; 1995 Sep; 16(1):4-8. PubMed ID: 12290471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
    Westhoff C; Jain JK; Milsom I; Ray A
    Contraception; 2007 Apr; 75(4):261-7. PubMed ID: 17362703
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Uniject as a delivery system for the once-a-month injectable contraceptive Cyclofem in Brazil.
    Bahamondes L; Marchi NM; de Lourdes Cristofoletti M; Nakagava HM; Pellini E; Araujo F; Rubin J
    Contraception; 1996 Feb; 53(2):115-9. PubMed ID: 8838489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
    Picardo C; Ferreri S
    Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Self-care provision of contraception: Evidence and insights from contraceptive injectable self-administration.
    Brady M; Drake JK; Namagembe A; Cover J
    Best Pract Res Clin Obstet Gynaecol; 2020 Jul; 66():95-106. PubMed ID: 32199705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate.
    Curtis KM; Nguyen A; Reeves JA; Clark EA; Folger SG; Whiteman MK
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):739-743. PubMed ID: 34014910
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current options for injectable contraception in the United States.
    Kaunitz AM
    Semin Reprod Med; 2001 Dec; 19(4):331-7. PubMed ID: 11727175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [An introductory clinical trial of three-monthly injectable contraceptive-depot medroxyprogesterone acetate].
    Shao Q; Jiang H; Fu W
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):36-9. PubMed ID: 11263172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contraceptive injections by community health workers in Uganda: a nonrandomized community trial.
    Stanback J; Mbonye AK; Bekiita M
    Bull World Health Organ; 2007 Oct; 85(10):768-73. PubMed ID: 18038058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statement on injectable contraception.
    International Planned Parenthood Federation IPPF
    IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Service Delivery Considerations for Introducing New Injectable Contraceptives Lasting 4 and 6 Months in Nigeria and Uganda: A Qualitative Study.
    Callahan RL; Burke HM; Lawton A; OlaOlorun FM; Mubiru F; Anyasi H; Wong CM; Bidashimwa D; Velarde M; Ruderman LW
    Glob Health Sci Pract; 2023 Dec; 11(6):. PubMed ID: 38135518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of injectable contraceptive users in a low-income population in Texas.
    Sangi-Haghpeykar H; Poindexter AN; Moseley DC; Bateman L; Reid ED
    Fam Plann Perspect; 1995; 27(5):208-11, 225. PubMed ID: 9104608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria.
    Hu E; Ikeako LC; Obiora-Okafor NC
    Niger J Med; 2012; 21(3):266-71. PubMed ID: 23304918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.